Current Strategies to Reduce Gastrointestinal Bleeding Risk Associated with Antiplatelet Agents

Drugs
Parth J ParekhDavid A Johnson

Abstract

Antiplatelet agents remain the cornerstone in the primary and secondary therapeutic intervention for cardiovascular disease. Some patients may be subjected to a year or more of dual antiplatelet therapy to reduce the risk of subsequent cardiovascular events. Patients on antiplatelet therapy have an increased risk of gastrointestinal bleeding; however, not all patients benefit from concomitant acid suppressive therapy. This review will provide an overview of the pharmacology of antiplatelet agents and outline patient risk profiles that ought to be considered when considering prophylactic therapy to reduce gastrointestinal toxicity. In addition, we discuss the current risk-reduction strategies intended to mitigate against the potential for related gastroduodenal injury.

References

Sep 1, 1991·The American Journal of Medicine·J F FriesB A Michel
Dec 1, 1985·Circulation·C PatronoL Forni
Nov 8, 1984·The New England Journal of Medicine·A K Pedersen, G A FitzGerald
Jun 1, 1982·The Journal of Clinical Investigation·P PatrignaniC Patrono
Dec 1, 1995·Journal of Clinical Pharmacology·I H BenedekD M Kornhauser
Jun 1, 1996·Gastroenterology Clinics of North America·J M Scheiman
Apr 13, 2000·Journal of Clinical Pharmacology·P H SluggJ Necciari
May 17, 2001·Proceedings of the National Academy of Sciences of the United States of America·L MaJ L Wallace
Dec 26, 2001·The New England Journal of Medicine·F Catella-LawsonG A FitzGerald
Sep 12, 2002·Clinical Pharmacokinetics·Zeruesenay DestaDavid A Flockhart
Oct 19, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Jean-Marie PereilloClaudine Picard
Jul 23, 2004·Thrombosis and Haemostasis·Dirk TaubertEdgar Schömig
Jan 22, 2005·The New England Journal of Medicine·Francis K L ChanJoseph J Y Sung
Apr 27, 2005·Seminars in Thrombosis and Hemostasis·Pierre Savi, Jean-Marc Herbert
Jun 14, 2005·Alimentary Pharmacology & Therapeutics·M VergaraX Calvet
Dec 2, 2005·The New England Journal of Medicine·Carlo PatronoColin Baigent
Jan 18, 2006·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Jessica L Fayer RehmelBarbara J Ring
Mar 29, 2006·Circulation·Neelima G Vallurupalli, Samuel Z Goldhaber
Nov 2, 2006·British Journal of Clinical Pharmacology·Joseph A JakubowskiKenneth J Winters
Jan 24, 2007·American Heart Journal·Marcel M C HovensMenno V Huisman
Mar 7, 2007·The American Journal of Gastroenterology·Angel LanasUNKNOWN Investigators of the Asociación Española de Gastroenterología (AEG)
Apr 4, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Nagy A FaridMark J Goldberg
Nov 6, 2007·The New England Journal of Medicine·Stephen D WiviottUNKNOWN TRITON-TIMI 38 Investigators
Mar 29, 2008·Clinical Drug Investigation·G DerayA Baumelou
Jan 30, 2009·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·David N JuurlinkMuhammad M Mamdani

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.